Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Acelity Names As Chief Financial Officer June 12, 2017 Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017 Sonoma Pharma Announces U.S. Commercialization Of Loyon For Relief Of Scaling, Burning And Itching Associated With Various Dermatoses Including Seborrhea And Seborrheic Dermatitis October 2, 2017
Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017
Sonoma Pharma Announces U.S. Commercialization Of Loyon For Relief Of Scaling, Burning And Itching Associated With Various Dermatoses Including Seborrhea And Seborrheic Dermatitis October 2, 2017
